Vanhoorelbeke Karen, Ulrichts Hans, Van de Walle Gerlinde, Fontayne Alexandre, Deckmyn Hans
Laboratory for Thrombosis Research, IRC, KU Leuven Campus Kortrijk, Kortrijk, Belgium.
Curr Pharm Des. 2007;13(26):2684-97. doi: 10.2174/138161207781662867.
The platelet receptor glycoprotein (GP)Ib-IX-V complex plays a dominant role in the first steps of platelet adhesion and arterial thrombus formation. Through its interaction with the multimeric plasma protein von Willebrand factor (VWF), which is bound to the damaged subendothelial structures, GPIb-IX-V tethers the platelets from the flowing blood thereby slowing them down. This step is a prerequisite for the collagen receptors to participate in firm adhesion resulting in the formation of a first platelet layer which is the basis for further thrombus formation. Recently, other ligands for GPIb-IX-V besides the extensively studied VWF have been identified, such as: alpha-thrombin, coagulation factor XII (FXII), high molecular weight kininogen (HMWK), factor XI (FXI), integrin Mac-1 and P-selectin. In this review, the interaction of GPIb-IX-V with its different ligands is described and the anticipated or demonstrated in vivo effects are discussed.
血小板受体糖蛋白(GP)Ib-IX-V复合物在血小板黏附及动脉血栓形成的起始步骤中起主导作用。通过与多聚体血浆蛋白血管性血友病因子(VWF)相互作用,VWF与受损的内皮下结构结合,GPIb-IX-V将流动血液中的血小板拴系住,从而使其速度减慢。这一步骤是胶原受体参与牢固黏附从而形成首个血小板层的前提条件,而首个血小板层是进一步血栓形成的基础。最近,除了被广泛研究的VWF之外,GPIb-IX-V的其他配体也已被鉴定出来,例如:α-凝血酶、凝血因子XII(FXII)、高分子量激肽原(HMWK)、因子XI(FXI)、整合素Mac-1和P-选择素。在本综述中,描述了GPIb-IX-V与其不同配体的相互作用,并讨论了预期的或已证实的体内效应。